{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:10:19Z","timestamp":1793823019093,"version":"4.6.1"},"reference-count":18,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    MK\u20108527 is a nucleoside reverse transcriptase translocation inhibitor (NRTTI) in clinical development. Two Phase 1 trials evaluated single (trial A) and multiple (trial B) ascending doses of MK\u20108527 in adults without HIV. In trial A, 34 participants were assigned to 1 of 4 panels and randomized to receive single oral doses of MK\u20108527 (0.5\u2013200\u2009mg) or placebo after fasting, over 3 dosing periods; 25\u2009mg was assessed after a high\u2010fat meal. In trial B, 32 participants were randomized to receive 3 once\u2010weekly (QW) oral doses of MK\u20108527 (between 5 and 40\u2009mg) or placebo. Safety and pharmacokinetics (PK) of MK\u20108527 and MK\u20108527\u2010triphosphate (TP) were assessed. MK\u20108527 was generally well tolerated with no serious adverse events. Plasma exposure of MK\u20108527 increased approximately dose\u2010proportionally, and intracellular exposure of MK\u20108527\u2010TP was slightly less than dose\u2010proportional over administered doses between 5 and 200\u2009mg. Participants who received MK\u20108527 with a meal showed a 41% decrease in\n                    <jats:italic>C<\/jats:italic>\n                    <jats:sub>max<\/jats:sub>\n                    with no effect on AUC\n                    <jats:sub>0\u2013168<\/jats:sub>\n                    , and a 20%, 22%, and 58% increase in intracellular MK\u20108527\u2010TP\n                    <jats:italic>C<\/jats:italic>\n                    <jats:sub>max<\/jats:sub>\n                    ,\n                    <jats:italic>C<\/jats:italic>\n                    <jats:sub>168<\/jats:sub>\n                    , and AUC\n                    <jats:sub>0\u2013168<\/jats:sub>\n                    , respectively. Across QW doses, plasma MK\u20108527 median\n                    <jats:italic>T<\/jats:italic>\n                    <jats:sub>max<\/jats:sub>\n                    ranged from 0.5 to 1\u2009h, and\n                    <jats:italic>t<\/jats:italic>\n                    <jats:sub>1\/2<\/jats:sub>\n                    was 24\u201381\u2009h; MK\u20108527\u2010TP median\n                    <jats:italic>T<\/jats:italic>\n                    <jats:sub>max<\/jats:sub>\n                    ranged from 10 to 24\u2009h on Day 15, and geometric mean apparent\n                    <jats:italic>t<\/jats:italic>\n                    <jats:sub>1\/2<\/jats:sub>\n                    was 216\u2013291\u2009h. Accumulation of intracellular MK\u20108527\u2010TP was modest (accumulation ratios [Day 15\/Day 1] for\n                    <jats:italic>C<\/jats:italic>\n                    <jats:sub>max<\/jats:sub>\n                    and AUC\n                    <jats:sub>0\u2013168<\/jats:sub>\n                    ranged from 1.1 to 1.6;\n                    <jats:italic>C<\/jats:italic>\n                    <jats:sub>168<\/jats:sub>\n                    from 1.2 to 2.4). Single and multiple QW doses of MK\u20108527 were generally well tolerated in adults without HIV. The safety and PK profiles of MK\u20108527 support continued clinical development.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Trial Registration:<\/jats:bold>\n                    EudraCT numbers: 2016\u2010004647\u201036 (trial A); 2018\u2010000846\u201020 (trial B)\n                  <\/jats:p>","DOI":"10.1111\/cts.70331","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:40:05Z","timestamp":1757976005000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety and Pharmacokinetics of\n                    <scp>MK<\/scp>\n                    \u20108527 in Adults Without\n                    <scp>HIV<\/scp>"],"prefix":"10.1111","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9111-4550","authenticated-orcid":false,"given":"Gillian","family":"Gillespie","sequence":"first","affiliation":[{"name":"Merck &amp; Co., Inc.  Rahway New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8083-0412","authenticated-orcid":false,"given":"Russ P.","family":"Carstens","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Rahway New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8319-5303","authenticated-orcid":false,"given":"Xiaowei","family":"Zang","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Rahway New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3300-1794","authenticated-orcid":false,"given":"Ryan","family":"Vargo","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Rahway New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2281-4115","authenticated-orcid":false,"given":"Yash","family":"Kapoor","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Rahway New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4468-2600","authenticated-orcid":false,"given":"Arinjita","family":"Bhattacharyya","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Rahway New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Francois","family":"Denef","sequence":"additional","affiliation":[{"name":"MSD Belgium  Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7062-3531","authenticated-orcid":false,"given":"Tom","family":"Reynders","sequence":"additional","affiliation":[{"name":"MSD Belgium  Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Vanhoutte","sequence":"additional","affiliation":[{"name":"SGS Life Science Services  Antwerp Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Rottey","sequence":"additional","affiliation":[{"name":"Ghent University Hospital  Ghent Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8403-267X","authenticated-orcid":false,"given":"Randolph P.","family":"Matthews","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Rahway New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5620-7092","authenticated-orcid":false,"given":"S. Aubrey","family":"Stoch","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Rahway New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8334-4815","authenticated-orcid":false,"given":"Marian","family":"Iwamoto","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Rahway New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"UNAIDS \u201cGlobal HIV statistics. Fact Sheet 2024 \u201daccessed January 27 2025 https:\/\/www.unaids.org\/en\/resources\/fact\u2010sheet."},{"key":"e_1_2_10_3_1","unstructured":"World Health Organization \u201cGlobal HIV Programme \u201dPre\u2010exposure prophylaxis accessed January 27 2025 https:\/\/www.who.int\/teams\/global\u2010hiv\u2010hepatitis\u2010and\u2010stis\u2010programmes\/hiv\/prevention\/pre\u2010exposure\u2010prophylaxis."},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3182986f69"},{"key":"e_1_2_10_5_1","unstructured":"EACS \u201cEuropean AIDS Clinical Society Guidelines 2023 Version 12.0 \u201daccessed January 27 2025 https:\/\/www.eacsociety.org\/guidelines\/eacs\u2010guidelines\/."},{"key":"e_1_2_10_6_1","volume-title":"DESCOVY [Product Insert]","year":"2022"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407001"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2411858"},{"key":"e_1_2_10_9_1","unstructured":"Centers for Disease Control and Prevention \u201cUS Public Health Service: Pre\u2010Exposure Prophylaxis for the Prevention of HIV Infection in the United States\u20102017 Update: A Clinical Practice Guideline \u201d(2025) accessed January 27 2025 https:\/\/www.cdc.gov\/hiv\/pdf\/risk\/prep\/cdc\u2010hiv\u2010prep\u2010guidelines\u20102017.pdf."},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461\u2010021\u201003357\u2010y"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/23259582211009011"},{"key":"e_1_2_10_12_1","unstructured":"I.Raheem K.Fillgrove G.O'Donnell et\u00a0al. \u201cDiscovery of MK\u20108527 a Long\u2010Acting HIV Nucleoside Reverse Transcriptase Translocation Inhibitor \u201dPresented at Conference on Retroviruses and Opportunistic Infections (CROI); March 3\u20106 2024; Denver Colorado USA."},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13048"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002755"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352\u20103018(19)30372\u20108"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00458\u201024"},{"key":"e_1_2_10_17_1","unstructured":"MSD \u201cMSD Data on File. Clinical Study Report (P001) \u201d (2019) Merck & Co. Inc. Rahway NJ USA."},{"key":"e_1_2_10_18_1","unstructured":"R. P.Carstens Y.Kapoor R.Vargo et\u00a0al. \u201cSingle Dose Administration of MK\u20108527 A Novel NRTTI in Adults With HIV\u20101 \u201dSingle Dose Administration of MK\u20108527 A Novel NRTTI in Adults With HIV\u20101. Presented at Conference on Retroviruses and Opportunistic Infections (CROI); March 3\u20139 2024 Denver CO USA."},{"key":"e_1_2_10_19_1","unstructured":"Y.Kapoor B.Evans R. P.Carstens et\u00a0al. \u201cMK\u20108527 PK\/PD Threshold and Phase 2 Dose Selection for Monthly Oral HIV\u20101 Preexposure Prophylaxis \u201dPresented at the Conference on Retroviruses and Opportunistic Infections (CROI); March 9\u201312 2025; San Francisco CA USA."}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70331","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cts.70331","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70331","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T10:59:20Z","timestamp":1769684360000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.70331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1111\/cts.70331"],"URL":"https:\/\/doi.org\/10.1111\/cts.70331","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"2025-02-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70331"}}